Cytokinetics

Ahead of adcomm, FDA raises uncertainties on benefit-risk profile of Cytokinetics' potential heart drug
Endpoints
Sun, 12/11/22 - 01:28 pm
FDA
Cytokinetics
heart failure
Omecamtiv Mecarbil
Go or no go? Mirati heads to the FDA
EP Vantage
Wed, 11/30/22 - 10:34 am
FDA
Mirati Therapeutics
Gilead Sciences
Coherus Biosciences
Roche
Biogen
TG Therapeutics
Ipsen
Novartis
BeiGene
Cytokinetics
FDA Review: Alnylam, Cytokinetics, Eli Lilly and More
BioSpace
Sun, 10/9/22 - 06:06 pm
FDA
Alnylam
Cytokinetics
Eli Lilly
Owlet
Boston Cell Standards
Kiromic Biopharma
Entera Bio
Transcenta Holdings
Kira Pharmaceuticals
Kite Pharma
Poxel
Seneca Therapeutics
Cytokinetics aims to become the Vertex of cardiovascular disease
EP Vantage
Thu, 06/16/22 - 10:19 am
Cytokinetics
Amgen
heart failure
Omecamtiv Mecarbil
cardiovascular disease
Cytokinetics hopes to resurrect omecamtiv
EP Vantage
Wed, 01/19/22 - 11:08 am
Cytokinetics
Omecamtiv Mecarbil
heart failure
Abandoned by Amgen, Cy­to­ki­net­ics lands $50M upfront deal for Chinese rights to heart failure prospect
Fierce Biotech
Tue, 12/21/21 - 10:34 am
Cytokinetics
heart failure
Omecamtiv Mecarbil
Amgen
China
Ji Xing Pharmaceuticals
Biogen leads the amyotrophic lateral sclerosis hopefuls
EP Vantage
Thu, 09/16/21 - 10:41 am
ALS
Amylx
Biogen
Ionis Pharmaceuticals
AB Science
Cytokinetics
Cytokinetics heart drug succeeds in mid-stage study, boosting shares
BioPharma Dive
Mon, 07/19/21 - 11:05 pm
Cytokinetics
clinical trials
CK-274
obstructive hypertrophic cardiomyopathy
ACC 2021: With Amgen out of the picture, Cytokinetics imagines supporting role for omecamtiv in heart failure
Fierce Biotech
Mon, 05/17/21 - 10:48 am
Amgen
Cytokinetics
ACC
Omecamtiv Mecarbil
Astellas quietly cuts Cytokinetics R&D pact as $450M-plus in biobucks goes up in smoke
Fierce Biotech
Mon, 05/3/21 - 10:51 am
Astellas
Cytokinetics
biobucks
Amgen severs 14-year Cytokinetics partnership, bailing on omecamtiv after mixed PhIII results
Endpoints
Mon, 11/23/20 - 10:16 pm
Amgen
Cytokinetics
omecamtiv
clinical trials
AHA 2020 – look out for the omecamtiv fault lines
EP Vantage
Mon, 11/16/20 - 10:13 am
AHA
Omecamtiv Mecarbil
Amgen
Cytokinetics
heart failure
Amgen and Cytokinetics claim heart drug success, but results widely disappoint
BioPharma Dive
Thu, 10/8/20 - 11:19 pm
Amgen
Cytokinetics
Servier
clinical trials
Omecamtiv Mecarbil
cardiovascular disease
Amgen heart drug passes interim check, setting up year-end readout
BioPharma Dive
Wed, 02/26/20 - 11:24 pm
Amgen
Omecamtiv Mecarbil
Cytokinetics
Cytokinetics' comeback attempt with second-gen drug is slammed by a PhII failure in ALS
Endpoints
Sun, 05/5/19 - 06:59 pm
Cytokinetics
clinical trials
reldesemtiv
ALS
Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure
Pharmaceutical Business Review
Fri, 02/22/19 - 10:04 am
Amgen
heart failure with reduced ejection fraction
Omecamtiv Mecarbil
Cytokinetics
Servier
After a crushing PhIII failure, Cytokinetics says its next-gen muscle drug is lining up well in PhII — but big challenges loom
Endpoints
Mon, 06/18/18 - 10:00 am
Cytokinetics
clinical trials
reldesemtiv
Tirasemtiv
spinal muscular atrophy
Astellas
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
Stat
Tue, 10/3/17 - 11:50 am
biotech
Axovant Sciences
intepirdine
SAGE Therapeutics
brexanolone
AbbVie
risankizumab
Global Blood Therapeutics
GBT-440
DBV Technologies
Viaskin Peanut
Cytokinetics
Amicus Therapeutics
ATB200
Spark Therapeutics
Bluebird Bio
Revance Therapeutics
RT002
Cytokinetics inches forward with heart failure program
BioPharma Dive
Thu, 08/3/17 - 10:57 am
Cytokinetics
Omecamtiv Mecarbil
Amgen
heart failure
Japan
Cytokinetics reports 4Q loss
Yahoo/AP
Tue, 02/16/16 - 07:45 pm
Cytokinetics
earnings

Pages